Physician profile
Phuc H Pham
NPI 1760456487
$5,856.62
in general payments reported to CMS, 2019-2025
36 companies · $695 in 2025
The $695 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $1,018 · 2021: $1,201 · 2022: $1,014 · 2023: $472 · 2024: $594 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,483.31 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $534.16 | 2019-2025 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $344.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $274.58 | 2019-2025 | |
| Abbvie INC. | $272.46 | 2019-2023 | |
| Abbott Laboratories | $269.20 | 2019-2024 | Perclose Proglide, Esprit |
| Lilly USA, LLC | $250.42 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $238.75 | 2021 | |
| Novo Nordisk INC | $238.20 | 2019-2025 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $210.16 | 2019-2023 | |
| Exact Sciences Corporation | $209.97 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $197.80 | 2019-2022 | |
| Amgen INC. | $165.50 | 2019-2025 | Evenity, Prolia, Repatha |
| Regeneron Healthcare Solutions, INC. | $145.33 | 2019-2025 | Evkeeza |
| Sanofi Pasteur INC. | $136.43 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $112.94 | 2025 | Nayzilam |
| Merck Sharp & Dohme LLC | $112.87 | 2019-2025 | Gardasil 9, Capvaxive |
| Allergan, INC. | $102.51 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $59.22 | 2022 | |
| Shield Therapeutics INC | $51.42 | 2023-2024 | Accrufer |
| Sanofi-Aventis U.S. LLC | $49.20 | 2020-2021 | |
| Seqirus USA INC | $46.83 | 2019-2025 | Fluad, Flucelvax |
| Medicure Pharma INC. | $44.52 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.55 | 2022-2024 | |
| Medtronic, INC. | $33.12 | 2025 | Symplicity G3 |
| Nevro Corp. | $29.12 | 2022-2023 | Senza |
| Mylan Specialty L.P. | $28.63 | 2023 | Yupelri |
| Amarin Pharma, INC. | $28.49 | 2019-2021 | |
| Medtronic Vascular, INC. | $26.54 | 2019 | |
| Agios Pharmaceuticals, INC. | $23.71 | 2025 | Pyrukynd |
| Teva Pharmaceuticals USA, INC. | $19.14 | 2019 | |
| Sonex Health, INC. | $17.20 | 2025 | Sx-One Microknife |
| Phathom Pharmaceuticals, INC. | $17.01 | 2024 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $15.20 | 2020 | |
| Phadia US INC. | $13.57 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phuc Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.